Hepatic decompensation during direct-acting antiviral therapy of chronic hepatitis C

Journal of Hepatology

Volumn 64, Issue 4, 2016, Pages 763-765

  Hoofnagle, Jay H ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Acute hepatic decompensation; Antiviral therapy; Cirrhosis; Hepatitis C; Lactic acidosis; Mitochondrial injury; Ribavirin; Severe adverse events; Sofosbuvir

Indexed keywords

ACETYLSALICYLIC ACID; BOCEPREVIR; DACLATASVIR; DASABUVIR; DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; DIDANOSINE; FIALURIDINE; INTERFERON; LEDIPASVIR; LINEZOLID; OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; PLACEBO; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; STAVUDINE; TELAPREVIR; TETRACYCLINE; VELPATASVIR; ZIDOVUDINE; ANTIVIRUS AGENT; URIDINE PHOSPHATE;

ADVERSE OUTCOME; ANTIVIRAL THERAPY; CHRONIC HEPATITIS C; DECOMPENSATED LIVER CIRRHOSIS; DIARRHEA; DISEASE SEVERITY; EDITORIAL; FATIGUE; HEADACHE; HEPATITIS C VIRUS; HUMAN; INSOMNIA; LACTIC ACIDOSIS; MITOCHONDRIAL TOXICITY; NAUSEA; NONHUMAN; PRIORITY JOURNAL; VIRAL CLEARANCE; COMBINATION DRUG THERAPY; HEPACIVIRUS; HEPATITIS C, CHRONIC;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; RIBAVIRIN; SOFOSBUVIR; URIDINE MONOPHOSPHATE;

EID: 84957049564     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.01.007     Document Type: Editorial

References (20)

1. AASLD/IDSA Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing and treating adults infected with hepatitis C virus Hepatology 62 2015 932 954
2. N. Afdhal, S. Zeuzem, P. Kwo, M. Chojkier, N. Gitlin, M. Puoti, and et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection N Engl J Med 370 2014 1889 1898
3. J.J. Feld, K.V. Kowdley, E. Coakley, S. Sigal, D.R. Nelson, D. Crawford, and et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin N Engl J Med 370 2014 1594 1603
4. S. Zeuzem, I.M. Jacobson, T. Baykal, R.T. Marinho, F. Poordad, M. Bourlière, and et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin N Engl J Med 370 2014 1604 1614
5. J.J. Feld, I.M. Jacobson, C. Hèzode, T. Asselah, P.J. Ruane, N. Gruener, and et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection N Engl J Med 373 2015 2599 2607
6. G.R. Foster, N. Afdhal, S.K. Roberts, N. Bräu, E.J. Gane, S. Pianko, and et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection N Engl J Med 373 2015 2608 2617
7. M.P. Curry, J.G. O'Leary, N. Bzowej, A.J. Muir, K.M. Korenblat, J.M. Fenkel, and et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis N Engl J Med 373 2015 2618 2628
8. M. Charlton, G.T. Everson, S.L. Flamm, P. Kumar, C. Landis, R.S. Brown Jr, and et al. SOLAR-1 Investigators. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease Gastroenterology 149 2015 649 659
9. V. Saxena, L. Nyberg, M. Pauly, A. Dasgupta, A. Nyberg, B. Piasecki, and et al. Safety and efficacy of simeprevir/sofosbuvir in hepatitis C-infected patients with compensated and decompensated cirrhosis Hepatology 62 2015 715 725
10. M.-W. Welker, S. Luhne, C.M. Lange, J. Vermehren, H. Farnik, E. Hermann, and et al. Lactic acidosis in patients with hepatitis C virus related cirrhosis and combined ribavirin/sofosbuvir treatment J Hepatol 64 2016 790 799
11. G.C. Funk, D. Doberer, N. Kneidinger, G. Lindner, U. Holzinger, and B. Schneeweiss Acid-base disturbances in critically ill patients with cirrhosis Liver Int 27 2007 901 909
12. < http://livertox.nih.gov/Phenotypes-lact.html >.
13. R. McKenzie, M.W. Fried, R. Sallie, H. Conjeevaram, A.M. Di Bisceglie, Y. Park, and et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B N Engl J Med 333 1995 1099 1105
14. S.J. Coats, E.C. Garnier-Amblard, F. Amblard, M. Ehteshami, S. Amiralaei, H. Zhang, and et al. Chutes and ladders in hepatitis C nucleoside drug development Antiviral Res 102 2014 119 147
15. D. Xu, T. Nishimura, S. Nishimura, H. Zhang, M. Zheng, Y.Y. Guo, and et al. Fialuridine induces acute liver failure in chimeric TK-NOG mice: a model for detecting hepatic drug toxicity prior to human testing PLoS Med 11 2014 31001628
16. C. Hézode, H. Fontaine, C. Dorival, F. Zoulim, D. Larrey, V. Canva, and et al. CUPIC Study Group. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis Gastroenterology 147 2014 132 142
17. M. Kalafeteli, G. Dusheiko, and P. Manousou Clinical decompensation after achieving SVR with sofosbuvir, daclatasvir and ribavirin in a patient with recurrent HCV post-liver transplant J Gastrointestin Liver Dis 24 2015 257 258
18. J.G. Stine, N. Intagliata, N.L. Shah, C.K. Argo, S.H. Caldwell, J.H. Lewis, and et al. Hepatic decompensation likely attributable to simeprevir in patients with advanced cirrhosis Dig Dis Sci 60 2014 1031 1035
19. J.K. Dyson, J. Hutchinson, L. Harrison, O. Rotimi, D. Tiniakos, G.R. Foster, and et al. Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use J Hepatol 64 2016 234 238
20. < http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm468757.htm >.